Abacus Pharma (A) Ltd Pharmaceutical Import Profile — Burundi (DGFT 2022–2026)

Name: Abacus Pharma (A) Ltd Pharmaceutical Import Records from India — 4 Products, $497.5K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Abacus Pharma (A) Ltd — Pharmaceutical Importer Profile (2026) | 4 Products, $497.5K Trade | TransData Nexus

Abacus Pharma (A) Ltd

Pharmaceutical Importer · Burundi · Advanced Antibiotics Focus · $497.5K Total Trade · DGFT Verified

Abacus Pharma (A) Ltd is a pharmaceutical importer based in Burundi with a total trade value of $497.5K across 4 products in 3 therapeutic categories. Based on 25 verified import shipments from Indian Customs (DGFT) records, Abacus Pharma (A) Ltd is the #1 buyer in 1 product including Volini. Abacus Pharma (A) Ltd sources from 23 verified Indian suppliers, with Ajanta Pharma Limited accounting for 20.2% of imports.

Abacus Pharma (A) Ltd — Import Portfolio & Supplier Network

Abacus Pharma (A) Ltd import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Abacus Pharma (A) Ltd?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Ajanta Pharma Limited	$962.7K	148	20.2%
Bharat Serums And Vaccines Limited	$587.3K	26	12.3%
Glenmark Pharmaceuticals Limited

What Formulations Does Abacus Pharma (A) Ltd Import?

Formulation	Value	Ships
Piricam 20MG CAPS piroxicam USP	$133.5K	3
Ascoril expectorant 100 ML batch no 10222580 10222791	$100.0K	2
Artefan tablets 20 120MG 90000pac x 1 x24 2160000 tablets artemether and lumefantrine tablets 20 120MG	$100.0K	2
Ridmal 40 320MG tablets 40000pac x 1 x 9 360000 tablets dihydroartemisinin and piperaquine phosphate	$100.0K	2
Oriprim tablets trimethoprim 80MG+sulphamethoxazole 400MG	$100.0K	2
Pharmaceuticals formulations -dynapar diclofenac sodium and paracetamol	$86.1K	2
Ascoril d cough syrup tz 100ML	$65.2K	2
Abadol 500 paracetamol tablets BP 500 MG	$59.5K	2
Zithroheal 500 MG tablets Each tablet contains azithromycin USP 500 MG qty 24000x1x3s	$50.0K	1
Z plaster roll 10 0 cm x 3 5 m zinc oxide adhesive plaster 10 0 cm x 3 5	$50.0K	1
Foligraf 1200iu recombinant human follicle stimulating hormone for injection r	$50.0K	1
Foligraf 75 IU recombinant human follicle stimulating hormone for	$50.0K	1
Foligraf md 1200 IU pre filled pen recombinant human follicle stimulating hormone injection ih	$50.0K	1
Pharmaceutical article / ods / product / item : prednisolone tablets BP 5MG	$50.0K	1
Dynapar diclofenac sodium and paracetamol tabs.10x10tab b/no 181574 to d181580 m/d.aug-2023 e/d.	$50.0K	1

Abacus Pharma (A) Ltd imports 371 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Volini	Brand Names & OTC Products	$200.0K	4	6.8%	1
2	Secnidazole	Advanced Antibiotics	$167.0K	12	0.6%	14
3	Trimethoprim	Advanced Antibiotics	$100.0K	2	0.4%	18
4	Tofacitinib	Advanced Oncology	$30.5K	7	0.8%	9

Abacus Pharma (A) Ltd imports 4 pharmaceutical products across 3 categories into Burundi totaling $497.5K. The company is the #1 buyer for 1 product: Volini.

Abacus Pharma (A) Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Abacus Pharma (A) Ltd is a leading pharmaceutical distributor and manufacturer operating across East Africa, including Burundi. Established in 1995, the company has grown to become a significant player in the region's healthcare sector. Headquartered in Kampala, Uganda, Abacus Pharma (A) Ltd has expanded its operations to Kenya, Tanzania, Rwanda, and Burundi, with a presence in multiple countries across the continent.

In Burundi, Abacus Pharma (A) Ltd has been operational since 2006, positioning itself as a key distributor in the country's pharmaceutical market. The company offers a comprehensive range of pharmaceutical products, including both locally manufactured and imported medicines, catering to various therapeutic needs. Abacus Pharma (A) Ltd's commitment to quality and accessibility has contributed to its growing influence in Burundi's healthcare landscape.

2Distribution Network

Abacus Pharma (A) Ltd has established an extensive distribution network across East Africa, including Burundi. In Burundi, the company operates a warehouse located in Bujumbura, the country's economic capital. This strategic location enables efficient distribution of pharmaceutical products throughout the region. The company's logistics capabilities are supported by a fleet of vehicles and partnerships with local distributors, ensuring timely delivery to various healthcare facilities and pharmacies. Abacus Pharma (A) Ltd's geographic coverage extends beyond Burundi, with operations in Uganda, Kenya, Tanzania, and Rwanda, facilitating a robust supply chain across East Africa.

3Industry Role

In Burundi's pharmaceutical supply chain, Abacus Pharma (A) Ltd functions primarily as a wholesaler and distributor. The company imports a diverse range of pharmaceutical products, including both generic and branded medicines, and supplies them to hospitals, pharmacies, and other healthcare providers across the country. Abacus Pharma (A) Ltd's role is crucial in ensuring the availability of essential medicines, thereby supporting the healthcare infrastructure in Burundi. While the company also engages in local manufacturing, its primary focus in Burundi remains on distribution and wholesale activities.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Abacus Pharma (A) Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Abacus Pharma (A) Ltd's sourcing strategy reveals a significant concentration on a select group of Indian pharmaceutical suppliers. The company's total import value from India amounts to $498,000 USD, distributed across 25 shipments and 4 products. The top five products imported from India include Volini ($200,000), Secnidazole ($167,000), Trimethoprim ($100,000), and Tofacitinib ($31,000). Notably, Volini accounts for 6.8% of the total import value, indicating a strong preference for this product.

This sourcing pattern suggests a strategic choice to maintain a focused product portfolio, potentially simplifying inventory management and strengthening supplier relationships. However, the heavy reliance on a limited number of suppliers may pose risks related to supply chain disruptions or price fluctuations. The shipment data indicates a stable relationship with these suppliers, as evidenced by the consistent import volumes over the period. Nonetheless, diversifying the supplier base could enhance resilience against potential supply chain challenges.

2Supply Chain Resilience

Abacus Pharma (A) Ltd's supply chain resilience is influenced by its sourcing strategy from Indian pharmaceutical manufacturers. The company's portfolio includes a diverse range of formulations, encompassing 371 unique products, which indicates a broad product offering. However, the concentration on a few key suppliers may expose the company to risks associated with supply chain disruptions, such as production delays or regulatory changes affecting these suppliers.

Importing Pharmaceuticals into Burundi — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Burundi

1Regulatory Authority & Framework

In Burundi, the primary regulatory authority overseeing pharmaceutical imports and distribution is the Ministry of Public Health and the Fight Against AIDS. This ministry is responsible for establishing and enforcing regulations related to the importation, registration, and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Law No. 1/10 of 2009, which outlines the conditions for the importation and commercialization of medicines.

The marketing authorization pathway for Indian generics involves several steps:

1. Product Registration: Pharmaceutical products must be registered with the Ministry of Public Health, providing detailed information on the product's composition, manufacturing process, and clinical efficacy.

2. Quality Control: Imported medicines are subject to quality control tests to ensure they meet the required standards.

3. Import License: An import license is required for each shipment, ensuring that only authorized entities can bring pharmaceutical products into the country.

4. Distribution Authorization: Companies must obtain authorization to distribute pharmaceutical products within Burundi, ensuring compliance with local regulations and standards.

2Import Licensing & GMP

Import licensing requirements in Burundi stipulate that all pharmaceutical products must be accompanied by an import license issued by the Ministry of Public Health. This license ensures that the products meet the necessary quality and safety standards before entering the market.

Abacus Pharma (A) Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Abacus Pharma (A) Ltd's product category focus is strategically aligned with the healthcare needs of the East African region. The company's imports from India are concentrated in three therapeutic categories:

1. Advanced Antibiotics (53.7%): This category addresses the growing demand for effective treatments against bacterial infections, a significant concern in the region.

2. Brand Names & OTC Products (40.2%): Offering well-known brands and over-the-counter medications caters to consumer preferences for trusted products.

3. Advanced Oncology (6.1%): Importing specialized oncology products reflects a commitment to providing treatments for cancer, a critical area of healthcare.

The market demand driving these imports includes the need for effective antibiotics to combat infectious diseases, the popularity of established brand-name products, and the rising incidence of cancer necessitating advanced treatments.

2Sourcing Profile

Abacus Pharma (A) Ltd's sourcing strategy emphasizes importing finished pharmaceutical formulations from India, focusing on generic drugs. This approach allows the company to offer affordable medicines while maintaining a diverse product portfolio.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Abacus Pharma (A) Ltd

What products does Abacus Pharma (A) Ltd import from India?

Abacus Pharma (A) Ltd imports 4 pharmaceutical products across 3 categories. Top imports: Volini ($200.0K), Secnidazole ($167.0K), Trimethoprim ($100.0K), Tofacitinib ($30.5K).

Who supplies pharmaceuticals to Abacus Pharma (A) Ltd from India?

Abacus Pharma (A) Ltd sources from 23 verified Indian suppliers. The primary supplier is Ajanta Pharma Limited (20.2% of imports, $962.7K).

What is Abacus Pharma (A) Ltd's total pharmaceutical import value?

Abacus Pharma (A) Ltd's total pharmaceutical import value from India is $497.5K, based on 25 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Abacus Pharma (A) Ltd focus on?

Abacus Pharma (A) Ltd imports across 3 categories. The largest: Advanced Antibiotics (53.7%), Brand Names & OTC Products (40.2%), Advanced Oncology (6.1%).

Get Full Abacus Pharma (A) Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.